57
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr.,
Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu
J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N
Engl J Med 2002; 347(13):975-82.
Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y,
Liang TJ, Hoofnagle JH. Progression of fibrosis in chronic hepatitis C.
Gastroenterology 2003; 124(1):97-104.
Goncales FL, Jr., Vigani A, Goncales N, Barone AA, Araujo E, Focaccia R, Oliveira
U, Coelho HS, Paixao J, Perez R, Lobato C, Weirich J, Rosa H, Borges A, Vila
R, Correa-Giannella ML, Ferraz ML. Weight-based combination therapy with
peginterferon alpha-2b and ribavirin for Naive, relapser and non-responder
patients with chronic hepatitis C. Braz J Infect Dis 2006; 10(5):311-6.
Granovsky MO, Minkoff HL, Tess BH, Waters D, Hatzakis A, Devoid DE, Landesman
SH, Rubinstein A, Di Bisceglie AM, Goedert JJ. Hepatitis C virus infection in
the mothers and infants cohort study. Pediatrics 1998; 102(2 Pt 1):355-9.
Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997; 26(3 Suppl 1):43S-
47S.
Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori
G, Bodenheimer H, Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin
A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in
chronic hepatitis C: a randomized study of treatment duration and ribavirin
dose. Ann Intern Med 2004; 140(5):346-55.
Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36(5 Suppl
1):S21-9.
Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner
JG, Park Y, Jones EA. Treatment of chronic non-A,non-B hepatitis with
recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;
315(25):1575-8.
Horoldt B, Haydon G, O'Donnell K, Dudley T, Nightingale P, Mutimer D. Results of
combination treatment with pegylated interferon and ribavirin in cirrhotic
patients with hepatitis C infection. Liver Int 2006; 26(6):650-9.
Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin
modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-
specific immune responses. J Gen Virol 1998; 79 ( Pt 10):2381-91.
Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH, Wu JC, Chang FY, Lee SD.
Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical
correlation. J Gastroenterol Hepatol 2001; 16(2):190-5.
Inglesby TV, Rai R, Astemborski J, Gruskin L, Nelson KE, Vlahov D, Thomas DL. A
prospective, community-based evaluation of liver enzymes in individuals with
hepatitis C after drug use. Hepatology 1999; 29(2):590-6.
Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V,
Korb G, MacSween RN, et al. Histological grading and staging of chronic
hepatitis. J Hepatol 1995; 22(6):696-9.
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ,
Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1
patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin
therapy. Hepatology 2006; 43(5):954-60.
Kamal SM. Acute hepatitis C: Prospects and challenges. World J Gastroenterol
2007; 13(48):6455-7.